President and CEO, Caprion Biosciences Inc.
A co-founder of Caprion, Martin has for over 15 years led Caprion’s technology development, laboratory operations and commercial strategy focused on specialized laboratory research services in the fields of proteomics, immune monitoring and personalized medicine. Profitable and rapidly growing based on its research contracts and strategic partnerships with over 75 global pharmaceutical and biotechnology companies, Caprion is also developing its own proprietary diagnostics tests for cancer, diabetes and infectious diseases. Since 2007, Martin has concluded 3 company acquisitions and has successively managed Caprion under the ownership of 3 leading healthcare private equity firms, including the recent sale of Caprion to GHO Capital in July 2017.
Prior to Caprion, Martin began his professional career as a management consultant with McKinsey & Company. He then initiated his career as a biotech entrepreneur at Advanced Bioconcept, initially as Vice-President of Sales & Marketing and then as General Manager following the company's acquisition by NEN Life Sciences (now part of Perkin-Elmer).
Martin is currently a member of the Board of Directors of Caprion, Softbox Systems, Mispro Biotech Services, Prevtec Microbia, Montreal InVivo, the Atlantic Cancer Research Institute and of the Centre for Commercialization of Cancer Immunotherapy. He is also a member of the Investment Committee of the Amorchem venture fund.
Martin earned his bachelor's degree in Economics from the University of Moncton prior to completing an M.A. in Economics and Politics at Oxford University as a Rhodes Scholar.
Senior Vice-President and Chief Financial Officer
Normand joined Caprion in July 2014. He has global responsibility for leading finance functions for the company, with particular focus on supporting strategic growth initiatives by representing the company with potential investors and business partners. Normand brings a solid financial background, impressive executive leadership skills and a vast array of connections in the life sciences industry and investment community. Prior to Caprion, Normand held the position of President & CEO at Victhom Human Bionics, a publically-traded medical device company and previously was the Vice President Finance of MOXXI Medical, CFO of NSI Global Inc. and Speedware Corporation Ltd and as a Director of High Tech Financing at BNP Paribas.
Normand received his Masters of Science Degree in International Finance from HEC Montreal and Bachelor of Business Administration in Finance from UQAM Montreal.
Senior Vice-President and Chief Business Officer
Carol has over 25 years of executive management experience in the diagnostic, medical device, and biotechnology industry. Carol joined Caprion in January 2014 as the Chief Business Officer and Sr. Vice President responsible for the commercial strategy and activities related to business development, marketing, product development, and customer service.
Prior to joining Caprion, Carol served as the Senior Vice President and General Manager for Asuragen's Genomic Services and CLIA Laboratory Division. From 2002 to 2007 Carol was a member of the senior management team at Ciphergen Biosystems Inc., a proteomic equipment and pharmacoproteomic research company. At Ciphergen she was responsible for diagnostic business development, sales and marketing, and assessing new potential diagnostic discoveries viable for commercialization. Carol served as the Vice President of Sales/Marketing for Dynacare Laboratories for three years where she was instrumental in expanding Dynacare's market share to a national ranking through acquisitions, strategic partnerships with hospitals, and organic sales growth nationwide. Carol started her diagnostic career at Roche Biomedical Laboratories where she was one of the top fifty General Managers from 1986 to 1996.
Carol received her Bachelor of Science Degree from Texas A&M University where she was a four year Letterman on the Women's Golf Team. She received her MBA-Information Technology Degree from University of Dallas in 2004.
Senior Vice-President and Corporate Development Officer
Patrick joined the Caprion team in 2011. He is a biopharmaceutical and investment executive with broad expertise in R&D and business development. He is leading the corporate strategies and the development of innovative diagnostics based on proteomic discoveries made at Caprion for indications such as cancer, as well as metabolic and infectious diseases.
Prior to joining Caprion, Patrick has worked with Pappas Ventures, a US-based venture capital firm that guided the development of more than 50 life science companies in therapeutics, diagnostics, medical devices and personalized medicine. He held positions as Vice-President of R&D at BioAxone and as Director of Pharmacology at Neurochem where he developed neuroprotective and neuroregenerative drugs for Alzheimer’s disease and spinal cord injury. He was also Assistant Professor in Neurology at the University of California in San Francisco where he worked on neurodegenerative diseases induced by prions and was part of the Nobel Laureate Team of Stanley Prusiner, Medicine and Physiology (1997).
Patrick has been involved in many innovative life science initiatives. He is one of the co-founders of the Personalized Medicine Partnership for Cancer and was intimately involved in the creation and financing of the new Neomed Institute. In recent years, he has held numerous advisory positions with diverse organizations such as the Campus des Technologies de la Santé, Quebec Consortium for Drug Discovery, Centre of Excellence for Commercialization and Research of the Montreal Neurological Institute and at Pharmacology Institute of Sherbrooke University. He is presently a member of the Board of Directors of Univalor.
Patrick holds a B.Sc. degree in Microbiology and Immunology from McGill University and a Ph.D. in Molecular Biology from the
University of Montreal. He has also
completed post-doctoral studies at the Max Planck Institute for Biophysical Chemistry in Germany.
Senior Vice-President and Chief Operating Officer
Lorella is responsible for scientific operations of Caprion’s proteomics site in Montreal, Québec. She oversees scientific and technical sample preparation/processing, mass spectrometry and bioinformatics and leads a team that provides complete offering from discovery through validation. She is also responsible for the Quality Management System (GLP) within the operation to support drug development programs (pre-clinical and clinical) for quantitative assessment of protein biomarker(s), biologics and biosimilars (PK assays). Validation of these types of assays as well as analysis of study samples are performed in accordance with FDA and EMA bioanalytical methods validation guidelines.
Before joining Caprion, Lorella was Vice-President of the Analytical Operations at Cirion BioPharma Research and was responsible for technology transfer, method development and validation of biomarker, PK and immunogenicity assays to support the development of biologic and biosimilar drug products at the pre-clinical and clinical stages. Lorella received her Ph.D. in biochemistry from the University of Montréal and has over 15 years’ experience in the CRO bioanalytical area for both small and large molecules. She has extensive knowledge of regulatory requirements for more than 500 validated methods.
Peter Krutzik, Ph.D.
Chief Scientific Officer, Primity Bio, A Caprion Company
Peter brings over 15 years of flow cytometry experience and innovation, including seminal publications and presentations in phospho-specific flow cytometry, cellular barcoding, and the application of cytometry to drug discovery. He has expertise in bringing complex cellular assays to early phase clinical trials, and building customized pharmacodynamic assays in blood samples for cell signaling, receptor occupancy, and deep immunophenotyping. More recently, Peter has brought the same rigor to the mass cytometry, or CyTOF, platform, making it a tool more readily accessible to translational and clinical scientists.
Peter is a co-founder of Primity Bio, which was acquired by Caprion Biosciences in 2018. At Primity, where he served as CEO, he helped to build the company from the ground up to become a recognized leader in providing advanced flow cytometry services to pharmaceutical and biotech customers. Prior to Primity, Peter earned his PhD in Molecular Pharmacology from Stanford University.
Vice-President, Research and Development, Primity Bio, A Caprion Company
Tom Wehrman heads the R&D activities at Primity Bio. His team develops and implements new discovery platforms to take full advantage of the high content capabilities of flow cytometry and their application to pre-clinical drug development. Using a combination of high parameter flow cytometry and an in-depth knowledge of immunology and assay development, the R&D group specializes in signaling analysis by flow cytometry, compound profiling, biomarker discovery, and sample analysis from pre-clinical animal models.
As a co-founder of Primity Bio, Tom spearheaded the development of Primity’s novel profiling platforms and established the commercial channels to foster Primity’s success.
Prior to Primity Bio, Tom was the Vice President of R&D at DiscoveRx where he transitioned his academic inventions for monitoring protein interactions and protein movement in mammalian cells, into an industry leading cell based assay portfolio for GPCR, kinase, and NHR drug targets. Tom earned his PhD in Molecular Pharmacology from Stanford University.
Vice-President, Flow Cytometry
Virginia Litwin joined Caprion in September 2017. She is an internationally recognized thought-leader in bringing “Cytometry from Bench-to-Bedside” through the implementation of state-of-the-art and robust processes.
Virginia co-founded the Flow Cytometry Action Program Committee (APC) within the American Association of Pharmaceutical Scientists (AAPS) and is a councilor for both the International Society for the Advancement of Cytometry (ISAC) and the International Clinical Cytometry Society (ICCS). In addition, she serves on the ICCS Advocacy Committee whose mission is to interface with regulatory agencies. She is also the chair of the Document Development Committee for a new Clinical Laboratory Standards Institute Guideline, H62- the Validation of Assays Performed by Flow Cytometry.
Virginia co-edited the book, Flow Cytometry in Drug Discovery and Development and a special issue of the Journal of Immunology Methods on Flow Cytometry Biomarkers and Translational Medicine and recently she was a guest editor for a special issue of Cytometry Part B: Clinical Cytometry, focusing on receptor occupancy.
In 2013, she was invited to present at the FDA workshop on clinical flow cytometry following the publication of one of the first papers on flow cytometry method and instrument validation. She will also be presenting at the upcoming NIST-FDA Flow Cytometry Workshop: Building Measurement Assurance in Flow Cytometry.
Virginia received a Ph.D. in Virology/Immunology from the University of Iowa and joined Lewis Lanier at DNAX as a post-doctoral fellow where she identified one of the first human KIR receptors. Later, at Progenics Pharmaceuticals, she was part of the team which characterized the role of CC-CKR5 in HIV viral entry. Prior to joining the Company, Virginia was the Senior Principal Scientist and global scientific leader for flow cytometry at Covance.List of Publications
- Green, C., Brown, L., Stewart, J., Litwin, V., and McClosky. T. Recommendations for the Validation of Flow Cytometric Testing During Drug Development: I Instruments. JIM, 363:104, 2011.
- O’Hara, D., Xu, Y. Lianz, E., Reddy, M., Wu, D., and Litwin, V. Recommendations for the Validation of Flow Cytometric Testing During Drug Development: II Assays. JIM, 363:120, 2011.
- Litwin, V. M. and Andahazy, J., 2011. Monitoring the Cellular Components of the Immune System during Clinical Trials-- A Translational Medicine Approach. in: Litwin, V., Marder, P. (Eds.), Flow Cytometry in Drug Discovery and Development. Wiley-Blackwell.
- Hill, C., Wu, D. Ferbas, J. Litwin, V. Reddy, M., 2011. Regulatory Compliance and Method Validation. in: Litwin, V., Marder, P. (Eds.), Flow Cytometry in Drug Discovery and Development. Wiley-Blackwell.
- Wood, B., Jevremovic, D., Béné, MC., Yan, M,. Jacobs, P., Litwin, V. Validation of cell-based fluorescence assays: Practice guidelines from the ICSH and ICCS. Cytometry Part B: 84B:315, 2013
- L. Brown, C. Green , N. Jones, J. Stewart, S. Fraser, K. Howell, Y. Xu, C. Hill, C. Wiwi, W. White, P. O’Brien, V. Litwin. Recommendations for the Evaluation of Specimen Stability for Flow Cytometric Testing During Drug Development. JIM, 418:1, 2015.
- J. Stewart, C. Green, N. Jones, M. Liang, Y. Xu, W. White, V Litwin, D. Wilkins, M. Moulard. K. Czechowska, D. Lanham, T. Mc Closkey, J. Ferbas, B. van der Strate, C. Högerkorp T Wyant, A.Lackey. Overview of Flow Cytometry Receptor Occupancy Assays and Their Utility in Drug Development. Cytometry Part B: 90B: 110, 2016.
- C. Green, J. Stewart, C. Högerkorp, A. Lackey, N. Jones, M. Liang, Y. Xu, W. White, J. Ferbas, M. Moulard, K. Czechowska, T. Mc Closkey, B. van der Strate, D. Wilkins, D. Lanham, T. Wyant, V. Litwin. Recommendations for the development and validation of flow cytometry-based receptor occupancy assays. Cytometry Part B: 90B: 141, 2016.
- B. van der Strate R. Longdin, M. Geerlings, N. Bachmayer, M. Cavallin, V. Litwin, M. Patel, W. Passe-Coutrin, C. Schoelch, A. Companjen, M. Scheel Fjording. Best practices in Performing Flow Cytometry in a regulated environment: feedback from experience within the EBF. Bioanalysis Bioanalysis (2017) 10.4155/bio-2017-0093 Epub ahead of print.
Vice President, Discovery
Eustache is responsible for the advancement of Caprion’s diagnostics development pipeline and is involved in the development of privately and publically funded biomarker discovery programs.
He has led the development of new biology applications for the ProteoCarta™ platform in diverse disease areas such as oncology, inflammation, and metabolic disease, and has broad experience in target protein and biomarker discovery. He was the Principal Investigator of Caprion’s NIH/NIAID and CQDM funded programs in infectious disease and diabetes. Prior to the development of the ProteoCarta™ platform Eustache led Caprion’s mad cow disease diagnostic development program, resulting in the development of conformation-specific antibodies against aberrantly folded prion protein.
Eustache holds a B.Sc. in Biology from Concordia University and a Ph.D. in Immunology from McGill University. He did post-doctoral research in immune system development and memory at the Howard Hughes Medical Institute at the University of Alabama at Birmingham with an award from the prestigious Irvington Institute for Immunological Research.
Vice-President, Business Development
Benoit Houle joined Caprion in 2009 as Senior Director and then Vice-President, Business Development. Subsequently, he was promoted to General Manager of Caprion’s European operations in Gosselies, Belgium.
Prior to joining the company, Benoit acquired extensive experience in the private biotech industry, occupying positions of Associate Director of Custom Services at BioSignal PerkinElmer, Director of Operations in charge of the Genome Quebec proteomics platform and Senior Director of Technology Development at Genizon
Benoit received his Ph.D. in molecular biology, studying molecular mechanisms of cancer, work that he pursued as a post-doctoral fellow at M.I.T. and the Fred Hutchinson Cancer Research Center.